Patients Derived Organoids as a Promising Tool to Tailor Ovarian Cancer Therapies (PANDORA).

C

Centro di Riferimento Oncologico - Aviano

Status

Enrolling

Conditions

Ovarian Cancer

Study type

Observational

Funder types

Other

Identifiers

NCT06229522
CRO-2022-45

Details and patient eligibility

About

The association of clinical, pathogenesis and mutational profile of patients affected by ovarian cancer have improved the armamentarium of therapies available for medical doctors. One of most remarkable advancements is represented by the introduction of PARP inhibitors in the front-line setting of advanced ovarian carcinoma. It is necessary to continue with this effort and introduce novel approaches to improve the survival rate as well as predictive biomarkers to approved therapies. Given the absence of predictive biomarkers to standard therapy, patients derived organoid could be a promising platform to test clinically available drugs and/or promising new molecules to explore the tumor sensibility in an ex-vivo model. The aim of this study is to correlate treatment sensibility measured in tumor derived organoids to clinical sensibility seen in real world patients.

Full description

The association of clinical, pathogenesis and mutational profile of patients affected by ovarian cancer have improved the armamentarium of therapies available for medical doctors. One of most remarkable advancements is represented by the introduction of PARP inhibitors in the front-line setting of advanced ovarian carcinoma. It is necessary to continue with this effort and introduce novel approaches to improve the survival rate as well as predictive biomarkers to approved therapies. Given the absence of predictive biomarkers to standard therapy, patients derived organoid could be a promising platform to test clinically available drugs and/or promising new molecules to explore the tumor sensibility in an ex-vivo model. The aim of this study is to correlate treatment sensibility measured in tumor derived organoids to clinical sensibility seen in real world patients.

Enrollment

150 estimated patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Signed informed consent form;
  2. Female sex;
  3. Age ≥18 years;
  4. Diagnosis of ovarian cancer;
  5. Availability of tumor sample or ascites that is planned to be stored in the Institutional Biobank for research purpose

Exclusion criteria

  1. Patients for which the tumor/ascites biobanking process could compromise the diagnostic assessments;
  2. Pregnancy or breast-feeding
  3. History of concomitant or previous malignancy in the last 5 years

Trial contacts and locations

1

Loading...

Central trial contact

Vincenzo Canzonieri, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems